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Abstract Measuring salivary cortisol is a simple, conve-
nient and accurate technique with potential value in mon-
itoring patients with hypercortisolism. This analysis reports
changes in late-night salivary cortisol (LNSC) during a
12-month, multicentre, Phase III study of patients with
Cushing’s disease who were randomized to pasireotide 600
or 900 lg sc bid. LNSC assessment was an exploratory
objective based on a single, optional measurement at
midnight ± 1 h on the same day as one of the 24-h urinary
free cortisol (UFC) measurements. Of 162 enrolled
patients, baseline LNSC was measured in 93. Sixty-seven
patients had levels above the upper limit of normal (ULN);
median baseline levels were 19.7 and 20.7 nmol/L in the
groups subsequently randomized to 600 lg (n = 40) and
900 lg (n = 27), respectively. Median LNSC levels
decreased from baseline to month 12; median changes in
patients who had baseline LNSC[ULN in the 600 and
900 lg groups were -13.4 nmol/L (–52.6 %; n = 19) and
-11.8 nmol/L (–56.1 %; n = 14), respectively. LNSC
normalized at months 6 and 12 in 25/67 (37.3 %) and 13/67
(19.4 %) patients, respectively; 10/25 and 8/13 patients
also had normalized UFC, and 7/25 and 4/13 had partial
UFC control (UFC[ULN and C50 % decrease from
baseline). There was a moderate correlation (r = 0.55) on
the log scale between individual patient LNSC and UFC
values when all time points were pooled. Pasireotide
decreased LNSC levels during 12 months of treatment.
Salivary cortisol may be a simple, convenient biomarker
for assessing treatment response in patients with Cushing’s
disease.
Keywords Pasireotide  Cushing’s disease  Salivary
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Introduction
The determination of 24-h urinary free cortisol (UFC)
levels is commonly used in the diagnosis [1] and subse-
quent treatment monitoring of patients with Cushing’s
disease [2, 3]. However, there are important limitations to
the use of UFC. For example, patients must collect a
complete 24-h urine sample, which can be a significant
challenge for ambulatory patients [4, 5]. Values may not be
reliable in patients with high fluid intake [6]. In addition, an
analysis in patients with Cushing’s disease demonstrated
high intra-patient variability (*50 %) in 24-h UFC mea-
surements that were collected on 4 days over a 2-week
period [7].
In recent years, the measurement of salivary cortisol has
become a vital tool in the diagnosis of patients with
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Cushing’s disease. High concordance has been shown
between UFC and late-night salivary cortisol (LNSC) when
screening for Cushing’s syndrome [8], and the measure-
ment of LNSC levels has high sensitivity (92–100 %) and
specificity (93–100 %) in the diagnosis of the disease [9–
13]. As with UFC, the collection of salivary samples is
simple, non-invasive and convenient as they can be
obtained by the patient at home and without the need for
specialized equipment. Cortisol levels in saliva are inde-
pendent of salivary flow rates; furthermore, salivary cor-
tisol is stable at room temperature for at least 2 weeks and
samples can be shipped to a reference laboratory for
assessment [14, 15].
To date, no large studies in Cushing’s disease have
reported on the value of salivary cortisol as a tool for
monitoring medical treatment response [16–18]. The cur-
rent analysis evaluates changes in LNSC levels during
treatment with the multireceptor-targeted [19] somatostatin
analogue pasireotide in a 12-month, Phase III study. In this
study, pasireotide treatment led to decreases in UFC levels
and improvements in the signs and symptoms of Cushing’s
disease [20].
Methods
Patients
Adult patients (aged C18 years) with a confirmed diagno-
sis of persistent, recurrent or de novo (if not surgical can-
didates) Cushing’s disease were enrolled. Cushing’s
disease was defined by a mean 24-h UFC level (calculated
from four samples collected within 2 weeks) that was C1.5
times the upper limit of normal (ULN), morning plasma
adrenocorticotropic hormone level C5 ng/L (C1.1 nmol/L)
and a confirmed pituitary source of Cushing’s syndrome.
Full details of the inclusion and exclusion criteria have
been reported previously [20].
The study was approved by the independent ethics
committee, research ethics board or institutional review
board at each centre and complied with the ICH Harmo-
nized Tripartite Guidelines for Good Clinical Practice, the
Declaration of Helsinki and local laws. All patients pro-
vided written informed consent.
Study design
This was a randomized, double-blind, multicentre, 12-month,
Phase III study (Clinicaltrials.gov: NCT00434148). Follow-
ing screening and appropriate washout of cortisol-lowering
medications, patients were randomized to subcutaneous (sc)
pasireotide 600 or 900 lg bid. At month 3, patients with UFC
levels B29 ULN continued on their randomized dose, dou-
ble-blind, until month 6. All other patients were unblinded
and their dose increased by 300 lg bid until month 6. At
month 6, patients could enter an open-label phase to month
12, during which time the dose could be titrated by 300 lg bid
up to a maximum of 1200 lg bid. Dose reductions in steps of
300 lg bid for drug-related adverse events (AEs) were per-
mitted throughout the study.
Objectives and assessments
The primary objective of the study was to assess the
efficacy of pasireotide sc (600 or 900 lg bid) as measured
by the proportion of patients with UFC B ULN at month
6; the results of the primary objective have been pub-
lished previously and so will not be reported here [20].
Key secondary objectives were to assess changes in
clinical signs and symptoms; these results have also been
published previously and so will not be reported here
[21].
A pre-specified exploratory objective of the study,
which is the focus of this report, was to evaluate LNSC
levels during pasireotide treatment. LNSC levels were
evaluated based on single, optional measurements taken
using the Salivette Cortisol system at midnight (±1 h)
during the same day as one of the 24-h UFC collections at
the following time points: baseline, 3, 6 and 12 months of
treatment. Patients were provided with an instruction sheet
telling them how to collect the saliva sample, which they
did before brushing their teeth or C30 min after, and
C30 min after eating or drinking; they were required to
keep the sample refrigerated.
LNSC levels were determined using enzyme-linked
immunosorbent assay (ELISA; RE52611, IBL-Hamburg
GmbH, Germany; normal range 0.83–8.3 nmol/L [derived
from 725 healthy subjects]; limit of detection 0.41 nmol/L;
intra-assay variability of 3.2–7.6 % at 7.0–80.8 nmol/L;
inter-assay variability of 6.2–9.1 % at 5.9–72.8 nmol/L;
cross-reactivity with cortisone 3.3 %). UFC levels were
measured by three central laboratories (Eurofins Technol-
ogy Services [Suzhou] Co Ltd, Suzhou, China, which
measured all the samples from Chinese patients, and
Eurofins Medinet BV, Breda, The Netherlands; CRL
Medinet Inc, Lenexa, KS, USA, which measured all other
samples) monthly for the first 6 months, then every
3 months thereafter. Levels were determined using high-
performance liquid chromatography (Alliance 2795 High
Throughput System, UV Waters 2487, Waters Corp, Mil-
ford, MA, USA; normal range 30–145 nmol/24 h; limit of
quantification 5 nmol/L; intra-assay variability of
0.9–6.1 % at 5–2000 nmol/L; inter-assay precision of
2.4–5.7 % at 15–2000 nmol/L).
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Statistical methods
Only patients with available LNSC measurements at
baseline were included in this analysis; these patients were
stratified according to whether baseline LNSC was BULN
or[ULN. UFC response at month 6 was defined based on
levels at month 6: control, UFC levels BULN; partial
control, UFC levels [ULN and C50 % reduction from
baseline; uncontrolled UFC, levels [ULN and \50 %
reduction from baseline. LNSC response at month 6 was
also defined based on levels at month 6: response, LNSC
levels BULN (i.e. normalized); non-response, LNSC levels
[ULN. If either UFC or LNSC values at month 6 were
missing, they were imputed based on the last available
measurement between months 3 and 6 inclusive. Change
from baseline in LNSC was initially calculated within each
patient, then the overall median change was calculated
based on these data.
The correlation between LNSC and UFC was evaluated
using Spearman’s rank correlation. Only patients with both
UFC and LNSC assessments within the same 24-h period
were included at each time point (i.e. baseline, months 3, 6,
9 and 12).
Results
Patients with available LNSC measurements
at baseline
Baseline characteristics
Of the 162 patients enrolled into the Phase III study [20],
baseline LNSC levels were available in 93 patients (6- and
12-month data were available from 62 and 45 patients,
respectively); of these, there were 15 de novo patients and
78 with persistent/recurrent disease. Forty-eight were ran-
domized to pasireotide 600 lg bid and 45 to pasireotide
900 lg bid (Table 1); median baseline LNSC levels in the
two dose groups were 17.3 and 10.3 nmol/L, respectively.
Effect of pasireotide on LNSC levels in the group overall
(n = 93)
LNSC levels decreased overall by a median of 3.6 nmol/L
(–31.9 %; n = 62) after 6 months of pasireotide treatment;
decreases in the 600 and 900 lg groups were 4.9 nmol/L
(–26.5 %; n = 34) and 2.4 nmol/L (–41.8 %; n = 28),
respectively (Table 2). The overall median decrease in
LNSC after 12 months of treatment was 5.3 nmol/L
(–29.2 %; n = 45); the decreases in the 600 and 900 lg
groups were 7.2 nmol/L (–42.2 %; n = 24) and 1.6 nmol/L
(–26.1 %; n = 21), respectively. Overall mean pasireotide
dose increased markedly in the 600 lg group from baseline
to month 9, then remained stable to month 12 (Table 2); by
month 12, mean daily dose was similar in the two treatment
groups.
Patients with baseline LNSC levels £ULN or >ULN
Of the 93 patients, 26 (28.0 %) had normal LNSC levels at
baseline (median level of 5.7 nmol/L; range 1.0–8.0).
Sixty-seven patients (72.0 %) had baseline LNSC levels
[ULN: 40 in the pasireotide 600 lg bid group and 27 in
the pasireotide 900 lg bid group.
Effect of pasireotide on LNSC levels in the group
with elevated baseline LNSC (n = 67)
In patients who had baseline LNSC levels[ULN, median
levels decreased from baseline to month 12 during pasir-
eotide treatment (Fig. 1). After 3 months, median LNSC
change was -8.4 nmol/L (–46.6 %; n = 57) overall, and
-5.9 nmol/L (–33.6 %; n = 34) and -12.6 nmol/L
(–66.7 %; n = 23) in the 600 and 900 lg groups, respec-
tively; the equivalent changes after 6 months were
-8.1 nmol/L (–53.6 %; n = 45), -6.8 nmol/L (–34.2 %;
n = 28) and -12.1 nmol/L (–63.8 %; n = 17). Overall
change after 12 months was -11.9 nmol/L (–52.6 %;
n = 33); changes in the 600 and 900 lg groups were
-13.4 nmol/L (–52.6 %; n = 14) and -11.8 nmol/L
(–56.1 %; n = 19), respectively.
Effect of pasireotide on LNSC levels in the group
with normal baseline LNSC (n = 26)
The median changes in patients with baseline
LNSC BULN were ?0.6 nmol/L (?8.1 %; n = 17),
Table 1 Patient demographics and characteristics at baseline in 93
patients with LNSC measurements available at baseline
Demographic variable Pasireotide
600 lg bid
(n = 48)
Pasireotide
900 lg bid
(n = 45)
Median age (years) 38.0 37.0
Male:female (n) 13:35 9:36
Race [n (%)]
Caucasian 34 (70.8) 30 (66.7)
Black 0 (0) 1 (2.2)
Asian 10 (20.8) 10 (22.2)
Other 4 (8.4) 4 (8.8)
Median time since diagnosis (months) 20.2 38.8
Previous surgery [n (%)] 35 (72.9) 37 (82.2)
Median LNSC level (nmol/L) 17.3 10.3
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?1.4 nmol/L (?23.4 %; n = 6) and ?0.6 nmol/L
(?8.1 %; n = 11) at month 6, and ?2.3 nmol/L (?42.7 %;
n = 12), ?1.9 nmol/L (?70.4 %; n = 5) and ?2.6 nmol/L
(?37.8 %; n = 7) at month 12.
Normalization of LNSC in patients with baseline
levels >ULN
By month 6, LNSC levels had normalized in 25 of the 67
patients who had baseline LNSC[ULN (37.3 %). Ten of
the 25 patients with normalized LNSC also had UFC
control, while seven patients had partial UFC control; the
remaining eight patients had uncontrolled UFC. At month
12, levels had normalized in 13 of the 67 patients who had
baseline LNSC[ULN (19.4 %; Fig. 2). Of these 13
patients, eight and four also had UFC control and partial
control, respectively; one patient had uncontrolled UFC.
Thirty-four patients did not have normalized LNSC levels
at month 6 (the remaining eight patients had missing values
at months 3 and 6). Five of the 34 patients had UFC con-
trol, while eight patients had partial UFC control; the
remaining 21 patients had uncontrolled UFC. At month 12,
20 patients did not have normalized LNSC levels (the
remaining 34 patients had missing values). Of these 20
patients, five and six also had UFC control and partial
control, respectively; nine had uncontrolled UFC.
In both dose groups, median LNSC levels had decreased
at 12 months in patients with controlled (–46.8 % in
600 lg group, n = 5; -29.4 % in 900 lg group, n = 14)
and partially controlled (–71.6 % in 600 lg group, n = 9;
-81.4 % in 900 lg group, n = 2) UFC, and increased in
uncontrolled patients (?48.9 % in 600 lg group, n = 10;
?33.1 % in 900 lg group, n = 5).
Correlations: LNSC and UFC
The Spearman’s rank correlation between LNSC and UFC
was r = 0.45 at baseline. Following 6 and 12 months of
pasireotide treatment, the correlation was r = 0.57 and
r = 0.33, respectively. When all time points were pooled
for all patients, the Spearman’s rank correlation was
r = 0.51 (Fig. 3a); this was r = 0.65 when restricted to
only patients with baseline LNSC[ULN (Fig. 3b).
When assessed based on absolute changes in LNSC and
UFC during pasireotide treatment, the Spearman’s rank
correlation was r = 0.24 and r = 0.58 at 6 and 12 months,
respectively. When all time points were pooled for all
patients, the Spearman’s rank correlation was r = 0.41.
The correlation between baseline LNSC and percentage
change in LNSC for patients who had baseline LNSC levels
[ULN was also assessed. The Spearman’s rank correlation
was r = -0.369 at month 6 and r = -0.654 at month 12,
Table 2 Median LNSC and mean pasireotide dose during treatment in the 93 patients with available LNSC measurements at baseline
Pasireotide 600 lg bid (n = 48) Pasireotide 900 lg bid (n = 45) Overall (n = 93)
Baseline Median LNSC [range (nmol/L)] 17.3 (1.7–552.7) 10.3 (1.4–549.5) 14.4 (1.4–552.7)
Month 3 n 40 38 78
Median LNSC [range (nmol/L)] 11.0 (0–132.2) 8.5 (0.8–82.2) 9.5 (0–132.2)
Absolute change from baseline –4.4 –1.9 –3.1
Percentage change from baseline –28.1 –28.7 –28.3
Mean dose ± SD [lg/day] 1133 ± 209 1705 ± 222 1412 ± 359
Month 6 n 34 28 62
Median LNSC [range (nmol/L)] 7.8 (0–71.2) 6.9 (0.8–42.3) 7.5 (0–71.2)
Absolute change from baseline –4.9 –2.4 –3.6
Percentage change from baseline –26.5 –41.8 –31.9
Mean dose ± SD [lg/day] 1394 ± 410 1821 ± 382 1587 ± 449
Month 9 n 26 25 51
Median LNSC [range (nmol/L)] 13.0 (1.4–33.8) 8.7 (0.6–408.3) 11.0 (0.6–408.3)
Absolute change from baseline –7.5 –1.1 –2.2
Percentage change from baseline –24.8 –19.7 –22.6
Mean dose ± SD [lg/day] 1627 ± 538 1776 ± 474 1700 ± 508
Month 12 n 24 21 45
Median LNSC [range (nmol/L)] 10.2 (1.4–37.2) 8.4 (1.9–57.4) 8.8 (1.4–57.4)
Absolute change from baseline –7.2 –1.6 –5.3
Percentage change from baseline –42.2 –26.1 –29.2
Mean dose ± SD [lg/day] 1675 ± 586 1771 ± 483 1720 ± 537
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whilst the correlation when all time points were pooled was
r = -0.418.
Discussion
This exploratory analysis from a subset of patients enrolled
in a large Phase III study demonstrated that 12 months of
pasireotide treatment led to an overall decrease in LNSC in
patients with baseline levels [ULN. In these patients,
LNSC levels had normalized in 35.8 % (n = 24/67) after
6 months of pasireotide treatment and in 39.4 % (n =
13/33) after 12 months. Although the value of LNSC in the
diagnosis of Cushing’s disease is known, there is a paucity
of data regarding its use as a tool for monitoring medical
treatment response. Indeed, there is a general lack of
guidance regarding the appropriate method for monitoring
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treatment of Cushing’s disease, although most available
studies have measured changes in UFC levels.
Previous assessment of the effect of medical therapy on
LNSC levels is limited to small studies of short duration and
the outcomes have been mixed [16–18]. In one analysis of
seven patients with elevated baseline LNSC (which corre-
lated significantly with baseline UFC levels; r = 0.97,
P = 0.0002), LNSC levels were reduced in 6/7 patients and
UFC levels were decreased in all seven patients after 15 days
of pasireotide treatment [17]. A prospective analysis of 14
patients who received cabergoline and ketoconazole com-
bination therapy found that LNSC levels decreased non-
significantly from baseline; levels remained above normal in
10/14 patients, even in those with normalized UFC [16].
Finally, in a study of patients who received stepwise medical
treatment with pasireotide, cabergoline and ketoconazole,
recovery of cortisol diurnal rhythm (CDR; defined by mid-
night serum and salivary cortisol levels of \75 % of the
09:00 value) was achieved after 80 days in 6/12 patients (1
receiving monotherapy, 1 combination therapy and 4 triple
therapy) with disturbed CDR at baseline. CDR did not
recover in the six remaining patients, despite the normal-
ization of UFC in five of them [18].
In the present study, the observed decrease in LNSC
mirrored the decrease in UFC levels that was noted in the
overall population; notably, LNSC levels decreased rapidly
(median decrease of 47 % by month 3 in patients with
elevated baseline LNSC), similar to the response observed
with UFC in the primary analysis [20]. Most of the patients
with normalized LNSC also achieved control or partial
control of UFC (17/25 [68.0 %] and 12/13 [92.3 %] at
months 6 and 12, respectively), which implies an associa-
tion between changes in LNSC and UFC levels. This was
supported by the correlation analysis, which suggested a
moderately good correlation (r = 0.55) between LNSC
and UFC throughout the pasireotide treatment period.
Overall, these data suggest that the measurement of LNSC
may have value when monitoring medical treatment
response in patients with Cushing’s disease. Notably, a
number of studies have demonstrated that the assessment
of LNSC is an accurate and superior approach to UFC for
detecting surgical failure/recurrence of Cushing’s disease
[22–26]. In one study, LNSC had 100 % sensitivity in
detecting treatment failure, compared with 71 % for UFC
[22]. The authors commented that LNSC measurement
may detect subtle changes in the dynamics of cortisol
secretion that might be missed by a broader evaluation of
cortisol secretion using UFC. Indeed, elevated LNSC levels
can be observed earlier (mean time of 38.2 months) than
elevations in UFC (mean time of 50.6 months) in patients
with recurrent Cushing’s disease [27].
Salivary cortisol is usually measured either by an
immunoassay (including radioimmunoassay, enzyme-
linked immunosorbent assay and electrochemiluminescent
immunoassay) or by liquid chromatography–tandem mass
spectrometry (LC–MS/MS). Irrespective of the assay used,
because of assay variability, it is important that each lab-
oratory develops its own specific reference range for LNSC
measurements. Immunoassays are easy to perform and less
expensive than LC–MS/MS [28]. In future, the use of
automated immunoassays may allow for wider use of
LNSC as a diagnostic tool for Cushing’s disease [25] and
may help increase its utility as a tool for monitoring
treatment. However, the immunoassays inevitably have
some cross-reactivity with other corticosteroids, such as
cortisone. The salivary glands express corticosteroid 11b-
dehydrogenase isozyme 2 (11b-HSD2), which converts
cortisol into biologically inactive cortisone; in fact, sali-
vary cortisone levels are 2- to 3-fold greater than salivary
cortisol levels. Despite the greater analytical specificity of
LC–MS/MS, we do not believe that it has clinical superi-
ority [29, 30] and immunoassays may actually have better
diagnostic sensitivity for the diagnosis of Cushing’s syn-
drome [31, 32]. Similar to UFC, salivary cortisol concen-
trations can be influenced by a variety of extrinsic factors
such as food, exercise, smoking and various emo-
tional/physical disturbances [33–35]. There is substantial
day-to-day variation in normal subjects, as well as patients
with Cushing’s syndrome [33–35]. Accordingly, current
guidelines and longitudinal clinical studies suggest that 2–4
measurements of LNSC should be obtained on different
days to confirm the presence or absence of endogenous
hypercortisolism.
A major limitation of this study was that because the
assessment of LNSC was an exploratory objective, levels
were only available from 57.4 % (93/162) of the overall
study population and, of those 93, only 45 had LNSC
assessments at 12 months. In addition, although patients
were instructed to take the salivary cortisol measurements
at ‘midnight ± 1 h’, no specific information was noted
about when each patient collected their salivary cortisol
sample in relation to the time they went to sleep. As the
study inclusion criteria were based on elevated mean UFC
(1.59 ULN) rather than LNSC levels, 67/93 patients whose
LNSC levels were measured had values[ULN at baseline.
Similarly, dose adjustments during the study were made
based on UFC rather than LNSC levels, which could
potentially create a bias. There was an imbalance in
baseline LNSC levels between the pasireotide 600 and
900 lg groups (17.3 and 10.3 nmol/L, respectively), which
reflects the imbalance seen with UFC in the primary
analysis [20]. Ideally, patients should have been stratified
for baseline UFC during the randomization process, which
may have prevented the observed imbalance in UFC and,
subsequently, LNSC across dose groups. The relatively
poor sensitivity of LNSC in our study may reflect the fact
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that only one sample was collected at that time. In addition,
the central assay used had a relatively high ULN (8.3 nmol/L),
which might be accounted for by cross-reactivity of the
salivary cortisol assay with cortisone (3.3 %); it may have
been preferable to use a validated diagnostic cut-off for
LNSC levels. Finally, because of the known day-to-day
variations in salivary cortisol measurements [33–35], it
would have been preferable for more than one LNSC mea-
surement to have been taken at baseline and each of the three
monthly time points. The Endocrine Society clinical prac-
tice guidelines recommend that at least two LNSC mea-
surements be made during the diagnosis of Cushing’s
disease [1].
The measurement of LNSC may be a simple, convenient
biomarker in Cushing’s disease. The results of this
exploratory analysis suggest that LNSC may have value in
monitoring medical treatment response in patients with
Cushing’s disease. Prospective studies evaluating LNSC
levels during medical therapy for Cushing’s disease are
warranted.
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